| 2712 | | Petroleum jelly; paraffin wax, microcrystalline petroleum wax, slack wax, ozokerite, lignite wax, peat wax, other mineral waxes and similar products obtained by synthesis or by other processes, whether or not colored: | | | | |
| 2826 | | V. SALTS AND PEROXYSALTS, OF INORGANIC ACIDS AND METALS | | | | |
| 2830 | | Sulfides; polysulfides, whether or not chemically defined: | | | | |
| 2844.10 | | Natural uranium and its compounds; alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds: | | | | |
| 2844.20.00 | | Uranium enriched in U235 and its compounds; plutonium and its compounds; alloys, dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | | Free | | Free |
| 2844.30 | | Uranium depleted in U235 and its compounds; thorium and its compounds; alloys, dispersions (including cermets), ceramic products and mixtures containing uranium depleted in U235, thorium, or compounds of these products: | | | | |
| 2844.40.00 | | Radioactive elements and isotopes and com- pounds other than those of subheadings 2844.10, 2844.20, and 2844.30; alloys, dis- persions (including cermets), ceramic products and mixtures containing these elements, isotopes or compounds; radioactive residues | | Free | | Free |
| 2902.90.20 | 00 | Acenaphthene, chrysene, cymene, dimethylnaphthalenes, fluoranthene, fluorene, indene, mesitylene, methylanthracene, methylnaphthalene, phenanthrene and pyrene | kg | Free | | Free |
| 2922.41.00 | | Lysine and its esters; salts thereof | | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2930.90.91 | 10 | Cysteine hydrochloride | kg | | | |
| 2933.41.00 | 00 | Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2935.00.10 | 00 | 2-Amino-N-ethylbenzenesulfonanilide; 5-Amino- α, α, α-trifluorotoluene-2,4-disulfonamide; Benzenesulfonamide; Benzenesulfonyl hydrazide; 2-Chloro-4-amino-5-hydroxybenzenesulfonamide; 2,5-Dimethoxysulfanilanilide; and Metanilamide | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4￠/kg + 41% |
| 2939.63.00 | 00 | Lysergic acid and its salts | kg | Free | | 25% |
| 3004 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: | | | | |
| 3004.40.00 | 60 | Medicaments primarily affecting the eyes, ears or respiratory system | kg | | | |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.90.91 | 22 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.90.91 | 50 | Medicaments primarily affecting the digestive system: | | | | |
| 3006.70.00 | 00 | Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | kg | 5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 25% |
| 3606 | | Ferrocerium and other pyrophoric alloys in all forms; articles of combustible materials as specified in note 2 to this chapter: | | | | |
| 3606.90.30 | 00 | Ferrocerium and other pyrophoric alloys | kg | 5.9% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 56.7% |
| 3802.90.20 | 00 | Activated clays and activated earths | kg | 2.5% | Free (A,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P,SG) | 0.6￠/kg + 30% |
